Infectious Disease

Another preclinical study demonstrates antibiotic potential of CBD

Source/Disclosures

Published by:

infectious disease news logo

sources:

Kavaliauskas P, et al. Abstract 2831. Presented at: ASM Microbe; June 9-13, 2022; Washington, D.C

Disclosures:
Kavaliauskas reports no relevant financial disclosures.

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on . ” data-action=”subscribe”> Subscribe

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

WASHINGTON — Another preclinical study has added evidence that cannabidiol, or CBD, may have potential as an antibiotic, researchers said at ASM Microbe.

Prior research has shown that CBD, the main non-psychoactive component in cannabis, has activity against gram-positive bacteria, including resistant strains of Staphylococcus aureus, Streptococcus pneumoniae and Enterococcus faecalis.

CBD and CBD oil_Adobe

CBD is a promising candidate as an antimicrobial compound that targets emerging and multidrug-resistant pathogens. Source: Adobe Stock.

Last year, a study published in Communications Biology showed for the first time that CBD could also kill a subset of gram-negative bacteria, including Neisseria gonorrhoeae.

“We have a long-lasting interest in the search of novel antimicrobial hits for further drug development,” Povilas Kavaliauskas, MSc, a research associate at Weill Cornell Medicine, told Healio. “We have recently developed a small molecule library that contained CBD as one of the investigational compounds. While screening this library on multidrug-resistant Staphylococcus aureus, we got a promising hit.”

Kavaliauskas and colleagues tested CBD’s activity against MRSA and vancomycin-intermediate S. aureus (VISA) strains selected to represent major emerging multidrug resistance mechanisms.

According to the researchers, pure CBD (98.6%) demonstrated good and selective antimicrobial activity (with minimal inhibitory concentrations [MICs] between 2 to 4 µg/mL) against all tested MRSA and VISA strains and was comparable or greater than vancomycin (MICs between 1 to 2 and 4 µg/mL, respectively). The researchers said the antimicrobial activity of CBD was not impacted by the pre-existing resistance phenotype in S. aureus.

Kavaliauskas acknowledged that CBD, being a cannabinoid, does raise some skepticism from the general population.

“As scientists, our goal is to provide the translational preclinical data that could benefit patients and especially those that have extensively drug-resistant infections,” Kavaliauskas said. “We are now seriously investigating CBD as an antimicrobial, and currently, CBD is one of the major hits for our hit-to-lead optimization pipeline.”

Kavaliauskas said that by using synthetic organic chemistry approaches, the researchers are using CBD as a key molecule to develop novel CBD-based small molecules with even more promising activity against emerging gram-positive pathogens. Currently, they are investigating the in-vivo efficacy of this investigational CBD formulation in mouse models.

“CBD and possibly other nonpsychoactive cannabinoids could be potentially explored as a valuable pharmacophore for the development of novel antimicrobial compounds targeting emerging and MDR pathogens,” Kavaliauskas said.

References:

Blaskovich MAT, et al. Commun Biol. 2021;doi:10.1038/s42003-020-01530-y.

Kavaliauskas P, et al. Abstract 2831. Presented at: ASM Microbe; June 9-13, 2022; Washington, D.C

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on . ” data-action=”subscribe”> Subscribe

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ASM Microbe

ASM Microbe

Related Articles